International Biotechnology Trust (IBT) announced its results for the year ended 31 August 2023. The share price total return rose by 3% over the financial year to the end of August 2023, while the benchmark NASDAQ Biotechnology Index (NBI) fell by 1.4% over the same period. The company’s Net Asset Value rose by 2.7%. Most of […]
Ailsa Craig and Marek Poszepczynski will provide a live presentation relating to the Company’s Annual Results via Investor Meet Company on 7th Nov 2023 at 1:30pm GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during […]
International Biotechnology Trust has decided to appoint Schroder Unit Trusts Limited as its fund manager and AIFM. Shareholders had told the board that they wanted continuity of the company’s investment approach under the existing investment management team and to retain the dividend policy. Ailsa Craig and Marek Poszepczynski (who have been lead managers on the […]
SV Health (manager and AIFM for International Biotechnology) has informed the trust that it wishes to focus on its core healthcare venture business – quitting the job of managing the fund. Ailsa Craig and Marek Poszepczynski, the current lead managers, want to stay on in the role. The board has agreed that they will continue […]
International Biotechnology reports a -6.9% return on NAV and -6.4% return to shareholders for the year ended 31 August 2022. However, it beat its performance benchmark, the NASDAQ Biotechnology Index (NBI), which returned -13.8%. This helped the trust claw back some of its underperformance relative to its benchmark over the past five years so that, […]
Tough year for International Biotechnology but confidence remains – International Biotechnology (IBT) has published its annual results for the year to 31 August 2021. During this time, the company’s NAV per share and share price returned 9.8% and 3.8% respectively whilst the Nasdaq Biotechnology Index returned 22.8%. The board said while this is a disappointing […]
International Biotechnology Trust (IBT) has delivered strong returns over the past 12 months, with the NAV up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The COVID-19 pandemic has focused attention on the sector as a number of companies search for effective treatments and vaccines. The […]
International Biotechnology Trust (IBT) has delivered strong returns over the past year; its net asset value (NAV) is up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The COVID-19 pandemic has focused attention on the sector as a number of companies search for effective treatments and […]
International Biotechnology Trust (IBT) has delivered strong returns over the past year, the NAV is up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The pandemic has focused attention on the sector as a number of companies search for effective treatments and vaccines. The sector has […]
International Biotechnology Trust’s (IBT) has reported full-year results, to 31 August 2020. IBT’s NAV per share and share price returned 22.4% and 18.7%, whilst the NASDAQ Biotechnology index (NBI) returned 20.6% (to 31 August 2020) and the FTSE All-Share index returned -12.6% (to 28 August 2020). The table below summarises IBT’s cumulative total return performance over […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated